Clinical Trials List
2024-09-02 - 2027-12-31
Phase I
Recruiting3
ICD-10C25.3
Malignant neoplasm of pancreatic duct
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9157.3
Malignant neoplasm of pancreatic duct
-
Trial Applicant
IQVIA RDS Taiwan Ltd.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2025/08/20
Investigators and Locations
Co-Principal Investigator
- 姜乃榕 Division of Hematology & Oncology
- Chien-An Liu Division of Radiology
- San-Chi Chen Division of Hematology & Oncology
- I-Cheng Lee Division of General Internal Medicine
- Ming-Huang Chen Division of Hematology & Oncology
- Shao-Jung Hsu Division of General Internal Medicine
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- YU-YUN SHAO Division of Hematology & Oncology
- TSUNG-HAO LIU Division of Hematology & Oncology
- SHIH-HUNG YANG Division of Hematology & Oncology
- 郭弘揚 Division of Hematology & Oncology
- 呂理駿 Division of Hematology & Oncology
- 莊建淮 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 劉奕廷 Division of Hematology & Oncology
- Chien-Jui Huang Division of Hematology & Oncology
- 顏志傑 Division of Hematology & Oncology
- Yan-Shen Shan Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
9 participants
-
Global
282 participants
